Hoth Therapeutics, Inc. - HOTH STOCK NEWS

Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company, announced that CEO Robb Knie will feature in an exclusive interview on The RedChip Money Report airing on Bloomberg Television on March 20 at 7 p.m. ET. The segment, reaching 73 million homes in the U.S. and 100 million in Europe, will cover Hoth's focus on targeted therapeutics for unmet medical needs, highlighting its pipeline including the BioLexa Platform and HT-001.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has entered into a research agreement with the University of Cincinnati Research Institute to conduct antimicrobial characterization studies for HT-006, a novel antibiotic targeting multi-drug resistant bacterial lung infections. The studies aim to expedite HT-006's development towards clinical use, addressing critical conditions like hospital-acquired pneumonia. Dr. Daniel Hassett will lead the research, which aligns with FDA guidelines for antibacterial therapies.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has partnered with REPROCELL Ltd. to evaluate the HT-003 therapeutic platform's effects on ulcerative colitis and Crohn's disease tissues. This collaboration aims to characterize therapies for inflammatory bowel diseases, which affect around 3 million adults in the U.S. The active ingredient in HT-003 shows anti-inflammatory properties targeting retinoic acid metabolism. Hoth is working on multiple studies to meet unmet patient needs in various indications.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has successfully closed a private placement, raising $15.0 million through the issuance of 7,594,937 shares of common stock at $1.975 each. The offering also includes warrants with an exercise price of $1.86 per share. Proceeds will be used for product development and general corporate purposes. Hoth's largest shareholder has extended a one-year lockup agreement, which may stabilize share prices. The company is required to file a registration statement for the resale of shares within 15 days.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a definitive agreement for a private placement of 7,594,937 shares of common stock and warrants to purchase the same number of shares at $1.975 each, expected to yield approximately $15 million. The placement is set to close around March 10, 2021. The gross proceeds will fund the development of Hoth's product candidates and general corporate purposes. The warrants will have an exercise price of $1.86 and a three-year term.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced progress on its preclinical study for HT-002, a peptide therapeutic aimed at preventing or treating COVID-19. Conducted at Virginia Commonwealth University, the study has identified three optimized peptide candidates that may inhibit the SARS-CoV-2 virus, with one showing low viral inhibition and no toxicity. The peptides are believed to be effective against emerging virus variants, and further in vitro testing is underway. Hoth continues to support this research through funding agreements with VCU.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has successfully completed recruitment for Cohort 1 of its first-in-human clinical trial using the BioLexa platform to treat atopic dermatitis (eczema). CEO Robb Knie emphasized the unmet need for effective topical therapies for mild to moderate eczema patients. The company is optimistic about revealing preliminary trial results later this year. Hoth's focus is on developing therapies for various medical conditions, including skin toxicities and COVID-19 treatment prospects.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has expanded its licensing agreement with North Carolina State University to globally develop treatments for mast cell-derived cancers and anaphylaxis. The new therapy, HT-KIT, targets the KIT receptor linked to several cancers and severe allergic reactions. Initial proof-of-concept data supports its effectiveness, with a focus on aggressive mast cell neoplasms. Hoth aims to address critical unmet patient needs and enhance its therapeutic pipeline through this strategic collaboration.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has engaged RedChip Companies, Inc. to enhance its investor relations efforts. RedChip, a leader in investor relations for microcap stocks, aims to leverage its extensive network to help Hoth achieve its capital market objectives. Hoth focuses on developing therapies for unmet medical needs, including conditions like atopic dermatitis and COVID-19. The company is positioned to improve patient quality of life through innovative treatments.